Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT00493402 Completed - Clinical trials for Hepatocellular Carcinoma

Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma

TACEforHCC
Start date: July 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy, safety, and patient reported outcomes (PRO) of different regimens of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).

NCT ID: NCT00484211 Completed - Clinical trials for Hepatocellular Carcinoma

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic hepatocellular carcinoma patients treated with NGR-hTNF as single agent. Safety will be established by clinical and laboratory assessment according to NCI-CTC criteria

NCT ID: NCT00479050 Completed - Clinical trials for Hepatocellular Carcinoma

Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm

TACE-RFA
Start date: January 2001
Phase: Phase 1
Study type: Interventional

Combined the chemoembolization and Radiofrequency ablation for the hepatocellular carcinoma greater than 3 cm,the ablation volume of coagulation necrosis can be significantly increased,which may be enable effective treatment of patients with HCC greater than 3 cm.

NCT ID: NCT00478374 Completed - Clinical trials for Hepatocellular Carcinoma

Sorafenib With TACE to Treat Hepatocellular Carcinoma

S-TACE
Start date: May 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the feasibility to combine sorafenib with transarterial chemoembolisation in patients suffering from hepatocellular carcinoma.The hypothesis is that sorafenib may prevent the development and growth of tumoral lesions not treated by chemoembolisation.

NCT ID: NCT00467974 Completed - Clinical trials for Hepatocellular Carcinoma

Transarterial Ethanol Ablation (TEA) Versus Transcatheter Arterial Chemoembolisation (TACE) for Hepatocellular Carcinoma

Start date: June 2007
Phase: Phase 3
Study type: Interventional

The current randomized controlled trial comparing LEM and TACE aims to evaluate the safety and efficacy of LEM as compared to TACE for treating patients with unresectable HCC.

NCT ID: NCT00464919 Completed - Clinical trials for Hepatocellular Carcinoma

Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)

Start date: April 2007
Phase: Phase 2
Study type: Interventional

The prognosis for patients with metastatic or locally advanced hepatocellular carcinoma (HCC) is poor. The role of conventional systemic chemotherapy has been very limited because most chemotherapeutic agents are in-effective and relative toxic to HCC patients who tend to have poor organ function reserves due to liver cirrhosis. The molecular-targeted therapy, which aims at deranged signaling pathways of cancer cells or their microenvironment, holds promise for HCC. Sorafenib (BAY 43-9006), a novel bi-aryl urea, is a potent inhibitor of VEGFR2 and Raf kinase. The clinical activity of sorafenib in HCC has been tested in a phase II study (Bayer study 10874), which enrolled a total of 137 advanced HCC patients. There were 4% of documented partial response, 5% of minor response, and 55% of stable disease. The 6- month progression -free for the cohort was 40%. Currently, there are two on-going large-scale randomized trials of sorafenib in advanced HCC patients worldwide.

NCT ID: NCT00441376 Completed - Clinical trials for Hepatocellular Carcinoma

A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver

Start date: February 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) of ThermoDox when used in combination with radiofrequency ablation (RFA) in the treatment of primary and metastatic tumors of the liver.

NCT ID: NCT00428220 Completed - Clinical trials for Non-Small Cell Lung Cancer

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Start date: July 2007
Phase: N/A
Study type: Interventional

This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.

NCT ID: NCT00361309 Completed - Clinical trials for Hepatocellular Carcinoma

SU011248 in Advanced Hepatocellular Carcinoma

Start date: April 2006
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to begin to collect information and try to learn whether SU011248 works in treating patients with advanced liver cancer. Laboratory studies have shown that SU011248 may block the growth of blood vessels in tumors, which may prevent tumors from growing any further.

NCT ID: NCT00357474 Completed - Clinical trials for Hepatocellular Carcinoma

Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to choose the preferred treatment modality for multiple, small hepatocellular carcinomas.